Losses up 86 per cent as Telix launches flagship drug

MELBOURNE: Revenues at cancer fighter Telix Pharmaceuticals have jumped 46 per cent to $7.6 million

To read the full story...SUBSCRIBE NOW

Existing Subscribers Login Below:

Log In